ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase ... (units in the fourthfiscal quarter . ...)

ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent

Date:9/9/2008

units in the fourth fiscal quarter".

"Our growth in revenues for the quarter," he continued, "was offset at the bottom line by a $1.0 million dollar increase in Research and Development spending year-over-year related to our veterinary stem cell initiative and salary and stock compensation charges for the newly created position Chief Technology Architect. In addition, interest income declined $265,000 versus last year due to decreased cash balances and declining interest rates."

Osgood noted that the Company has achieved several important milestones recently, including receiving a CE-Mark enabling commercial sales of its MarrowXpress(TM), or MXP(TM), in Europe, and authorization from the FDA to initiate commercial sales of the device in the U.S. The MXP is used for concentrating stem cells from bone marrow at both the point-of-care and in a laboratory setting.

"In addition, we have appointed more than a dozen new distributors for our BioArchive System following the restructuring of our agreement with GE Healthcare, giving us distributor relationships in nearly all of our key international markets. Many of these distributors previously sold one or more of our offerings-including the BioArchive-and have established relationships in their markets," Osgood noted.

Osgood said the Company realized a number of key accomplishments in its growth strategy during fiscal 2008, including:

-- Amending its distribution agreement with GE Healthcare and achieving

higher manufacturing output of its AXP bagsets.

-- Developing and receiving regulatory approval of the MXP and initiating

discussions with customers and clinical study investigators.

-- Launching Vantus(TM), Inc., a subsidiary that is a collaboration with

the Center for Equine Health at the University of California, Davis,

that will offer stem cell laboratory services and point-of-care bone

marrow and peripheral blood processi
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))

Post Your Comments:

ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase ...(units in the fourthfiscal quarter . ...)